ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
New strategies in hepatocellular carcinoma: genomic prognostic markers.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.The Lancet. Oncology · 2012Guideline
- Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2014Trial
- Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.World journal of surgical oncology · 2025Review
- Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma.Clinical and molecular hepatology · 2025Article
- Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Article
- Advances in the application of Let-7 microRNAs in the diagnosis, treatment and prognosis of leukemia.Oncology letters · 2022Review
- Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma.JAMA network open · 2021Article
- DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle.Cell cycle (Georgetown, Tex.) · 2021Article
- Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response.Abdominal radiology (New York) · 2021Review
- miR-3677-5p promotes the proliferation, migration and invasion of hepatocellular carcinoma cells and is associated with prognosis.Experimental and therapeutic medicine · 2021Article
- Liver cancer stem cells: Recent progress in basic and clinical research.Regenerative therapy · 2021Review
- COMMD10 inhibits tumor progression and induces apoptosis by blocking NF-κB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma.Clinical and translational medicine · 2021Article
- Radiomics of hepatocellular carcinoma.Abdominal radiology (New York) · 2021Review
- Development of machine learning-based clinical decision support system for hepatocellular carcinoma.Scientific reports · 2020Article
- Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma.BMC cancer · 2020Article
- Prognostic and Therapeutic Potentials of OncomiRs Modulating mTOR Pathways in Virus-Associated Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
- An Integrating Immune-Related Signature to Improve Prognosis of Hepatocellular Carcinoma.Computational and mathematical methods in medicine · 2020Article
- Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency.Liver cancer · 2019Article
- Radiomics and radiogenomics of primary liver cancers.Clinical and molecular hepatology · 2019Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.